
11 Jan 2019 Research
Myelofibrosis: Finding new ways to treat patients
Myelofibrosis is a fatal bone marrow cancer. The disease is caused by excessive secretion of factors by cancerous platelet-producing cells called megakaryocytes. These secretions cause the replacement of normal bone marrow tissue with fibrous scar tissue.
Dr Chen’s team can successfully recreate this pathological bone marrow environment in the laboratory, and their preliminary research data shows that reduced levels of a protein complex called FANCcore leads to more myelofibrosis.
Dr Chen’s team hypothesise that loss of the protein complex FANCcore increases the growth of myelfibrosis by altering megakaryocytes. Dr Chen uses both human tissue cultures and mouse models to examine the cellular and molecular changes to megakaryocytes following the absence of the FANCcore complex and to understand how these changes cause myelofibrosis.
The team hopes that by focusing on the role of FANCcore in megakaryocyte biology, they can reveal new ways to treat myelofibrosis.
Related posts
27 August 2020
Leukaemia UK appoints new CEO
The trustees of Leukaemia UK are delighted to announce that they have appointed Fiona Hazell as CEO of Leukaemia UK. Fiona brings a strong track record in not-for-profit leadership, starting her role on 9th September 2020.
19 September 2023
“Fundraising never tasted so good!”: Star-studded evening raises over £235,000 for life-saving leukaemia research
Chefs and celebrities mingled at The Dorchester last night for a gastronomic spectacular in aid of Leukaemia UK, raising over £235,000 to support world-class research into the devastating disease. Who’s…
9 November 2017
Leukaemia UK is the new name for the ‘Elimination of Leukaemia Fund’
We are a leading charity making a difference to families affected by leukaemia, lymphoma, myeloma and other blood cancers.
11 January 2019
Myelofibrosis: Finding new ways to treat patients
Dr Edwin Chen, University of Leeds and John Goldman Fellow